In vivo modulation of polyclonal activation of lymphocytes by SOAz, a cyclophosphazene derived drug. Prevention of murine glomerulonephritis induced by chronic injections of lipopolysaccharide.
The effects of a cyclophosphazene derived drug (SOAz), on the polyclonal activation of B lymphocytes induced by bacterial lipopolysaccharide (LPS) have been studied in C57B1/6 mice. It has been found that this drug is able to inhibit the polyclonal stimulation of lymphocytes and a dose-dependent effect has been observed. The therapeutic effects of SOAz injected five times a week at 40 mg/kg/day have been investigated in mice chronically injected with LPS (twice a week, 2.5 mg/kg/day) which developed an immune complex type of glomerulonephritis. A marked prevention of glomerular lesions and of deposits of IgM and IgG, and of the third complement component has been found in mice treated with SOAz as compared to not treated mice.
D000818:Animals; D000936:Antigen-Antibody Complex; D001389:Azirines / Q000494:pharmacology*; D001402:B-Lymphocytes / Q000276:immunology*; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D005921:Glomerulonephritis / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D007136:Immunoglobulins / Q000032:analysis; D007668:Kidney / Q000473:pathology; D008070:Lipopolysaccharides; D008213:Lymphocyte Activation / Q000187:drug effects*; D051379:Mice; D008810:Mice, Inbred C57BL; D013997:Time Factors
D000936:Antigen-Antibody Complex; D001389:Azirines; D007136:Immunoglobulins; D008070:Lipopolysaccharides; C035161:pentazirinocyclodiphosphathiazene